STOCK TITAN

Exact Sciences Corp - EXAS STOCK NEWS

Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.

Exact Sciences Corporation (EXAS) delivers innovative cancer diagnostics through products like Cologuard® and Oncotype DX®. This page provides investors and healthcare professionals with essential updates on the company’s advancements in early cancer detection.

Find curated press releases and news covering financial results, regulatory milestones, product innovations, and strategic partnerships. Our repository ensures timely access to developments impacting precision oncology and noninvasive screening technologies.

Stay informed about EXAS’ role in molecular diagnostics, including updates on clinical studies, technology licensing agreements, and market expansion efforts. All content is verified for accuracy and relevance to support informed decision-making.

Bookmark this page for streamlined access to Exact Sciences’ latest developments. Check back regularly for authoritative updates directly affecting the future of cancer screening and diagnostic solutions.

Rhea-AI Summary
Exact Sciences Corp. (NASDAQ: EXAS) will present new data and study results at the 2023 annual San Antonio Breast Cancer Symposium (SABCS). The data includes updated TAILORx follow-up data, concordance analysis supporting the generation of Oncotype DX results from core needle biopsy, ADAPTcycle trial data, and prospective trial data regarding the potential omission of radiation therapy after surgery in certain patients with ductal carcinoma in situ (DCIS). The company aims to refine distant recurrence risk estimates, personalize treatment decisions, and expand the number of breast cancer patients able to forgo chemotherapy post-surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of Delaware, seeking damages and a court order to stop Geneoscopy from infringing on Exact Sciences' U.S. Patent No. 11,634,781. The patent covers methods for processing fecal samples at home for subsequent analysis in a clinical laboratory, central to Exact Sciences' Cologuard® stool DNA-based colorectal cancer screening test. After a reexamination by the USPTO, Geneoscopy's challenge to the patent was rejected, confirming its patentability for Exact Sciences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.39%
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. reports record revenue of $628 million in the third quarter of 2023, delivering over 1 million test results. Full-year revenue and adjusted EBITDA guidance raised by $28 million and $25 million, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) announced that company management will participate in several upcoming conferences and invited investors to participate by webcast. The conferences include Stifel Healthcare Conference, Jefferies London Healthcare Conference, Piper Sandler 35th Annual Healthcare Conference, and Evercore ISI HealthCONx Conference. The webcasts can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
conferences
-
Rhea-AI Summary
Exact Sciences Corp. announces late-breaking data from the BLUE-C trial showing the next-generation Cologuard test met all study endpoints, demonstrating 94% sensitivity for colorectal cancer at 91% specificity. Results show next-generation Cologuard test superior to FIT in sensitivity for colorectal cancer and pre-cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. to present new data on early cancer detection and genomic testing at ESMO Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
Rhea-AI Summary
Exact Sciences Corp. to release Q3 2023 financial results on November 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
-
Rhea-AI Summary
Exact Sciences Corp. to present late-breaking data on next-generation Cologuard at the ACG Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
conferences
-
Rhea-AI Summary
Exact Sciences acquires Resolution Bioscience to enhance cancer treatment solutions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
none
Rhea-AI Summary
Exact Sciences Corp. to participate in Baird Global Healthcare Conference on September 12, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
conferences
Exact Sciences Corp

Nasdaq:EXAS

EXAS Rankings

EXAS Stock Data

8.22B
183.06M
1.07%
100.78%
5.74%
Diagnostics & Research
Services-medical Laboratories
Link
United States
MADISON